- Home
- DNP vs KNSA Comparison
DNP vs KNSA Comparison
Compare DNP & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNP | KNSA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.9B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DNP | KNSA |
|---|---|---|
| Price | $10.01 | $73.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $98.00 |
| AVG Volume (30 Days) | ★ 783.2K | 530.1K |
| Earning Date | 01-01-0001 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $47.02 |
| Revenue Next Year | N/A | $22.84 |
| P/E Ratio | ★ N/A | $286.80 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $9.23 | $35.53 |
| 52 Week High | $11.16 | $84.06 |
Technical Indicators
Market Signals| Indicator | DNP | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 36.40 |
| Support Level | $10.05 | $43.24 |
| Resistance Level | $10.17 | $81.42 |
| Average True Range (ATR) | 0.15 | 3.30 |
| MACD | 0.06 | -0.49 |
| Stochastic Oscillator | 85.09 | 7.99 |
Price Performance
Historical ComparisonAbout DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.